Table 2.
Association between single nucleotide polymorphisms (SNPs) in the NPAS2 gene and clinical outcome in Chinese patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization (n = 448)
| SNP | Genotype and best-fitting model | Death/total 339/448 | Death HR† (95%CI) | P-value‡ |
|---|---|---|---|---|
| rs9223 | WW | 200/270 | Ref. | |
| WV | 122/156 | 1.03 (0.82–1.30) | 0.790 | |
| VV | 17/21 | 1.03 (0.62–1.70) | 0.910 | |
| Dominant | 1.03 (0.83–1.28) | 0.780 | ||
| rs1053096 | WW | 105/143 | Ref. | |
| WV | 165/220 | 1.08 (0.85–1.39) | 0.520 | |
| VV | 68/82 | 1.55 (1.14–2.12) | 0.005 | |
| Recessive | 1.48 (1.13–1.94) | 0.004 | ||
| rs1562313 | WW | 198/260 | Ref. | |
| WV | 115/157 | 0.87 (0.69–1.09) | 0.230 | |
| VV | 25/30 | 0.90 (0.59–1.37) | 0.620 | |
| Dominant | 0.87 (0.7–1.09) | 0.220 | ||
| rs2305158 | WW | 226/298 | Ref. | |
| WV | 94/128 | 1.12 (0.88–1.43) | 0.360 | |
| VV | 19/22 | 1.63 (1.01–2.63) | 0.040 | |
| Dominant | 1.18 (0.94–1.49) | 0.150 | ||
| rs2305160 | WW | 215/294 | Ref. | |
| WV | 107/133 | 1.61 (1.26–2.05) | ||
| <0.001 | ||||
| VV | 7/9 | 2.15 (1.00–4.64) | 0.050 | |
| Dominant | 1.63 (1.29–2.07) | <0.001 | ||
| rs3811558 | WW | 98/132 | Ref. | |
| WV | 163/208 | 1.05 (0.82–1.35) | 0.710 | |
| VV | 71/101 | 1.07 (0.78–1.46) | 0.670 | |
| Dominant | 1.06 (0.83–1.34) | 0.660 |
†
Adjusted for age, sex, hepatitis B virus infection, portal vein tumor thrombus, tumor stage, serum α-fetoprotein, and treatment.
‡
Significant P-values (<0.05) are in bold. CI, confidence interval; HR, hazard ratio; Ref., reference; VV, homozygous variant; WV, heterozygous variant; WW, homozygous wild-type.